David Jablons moderates this live event, which presented data about the development of a molecular assay based on resected tumor RNA expression from simple paraffin-fixed tissue samples. This is integrated into an algorithm that can assign a risk score for recurrence. This molecular risk score is fully independent of standard TNM staging and does not rely on any other clinical parameters. The assay has been widely validated in thousands of patients and demonstrates both significant prognostic information and the predictive benefit of adjuvant platinum based chemotherapy in high risk patients, as identified by this assay.
The Beat With Joel Dunning Ep. 54
The Beat With Joel Dunning Ep. 53
The Beat With Joel Dunning Ep. 52
The Beat With Joel Dunning Ep. 51
The Beat With Joel Dunning Ep. 50
The Beat With Joel Dunning Ep. 49
The Beat With Joel Dunning Ep. 48: Live From the SCTS Annual Meeting
The Beat With Joel Dunning Ep. 47
The Beat With Joel Dunning Ep. 46
The Beat With Joel Dunning Ep. 45
The Beat with Joel Dunning Ep. 44
The Beat with Joel Dunning Ep. 43
The Beat with Joel Dunning Ep. 42
Live from STS: The Beat with Joel Dunning Ep. 41
The Beat with Joel Dunning Ep. 40
The Beat with Joel Dunning Ep. 39
The Beat with Joel Dunning Ep. 38
The Beat with Joel Dunning Ep. 37
The Beat with Joel Dunning Ep. 36
The Beat with Joel Dunning Ep. 35
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive